Meta-Analysis
Copyright ©The Author(s) 2019.
World J Meta-Anal. Feb 22, 2019; 7(2): 51-65
Published online Feb 22, 2019. doi: 10.13105/wjma.v7.i2.51
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flowchart outlining the study selection process according to the Preferred Reporting Items for Systematic Reviews guidelines. DCE-MRI: Dynamic contrast-enhanced magnetic resonance imaging; DSC-MRI: Dynamic susceptibility contrast magnetic resonance imaging.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Sensitivity and specificity of dynamic contrast-enhanced magnetic resonance imaging and dynamic susceptibility contrast magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Likelihood ratio + and likelihood ratio - of dynamic contrast-enhanced magnetic resonance imaging and dynamic susceptibility contrast magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Diagnostic odds ratio of dynamic contrast-enhanced magnetic resonance imaging and dynamic susceptibility contrast magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Summary receiver operating characteristic curve for dynamic contrast-enhanced magnetic resonance imaging and dynamic susceptibility contrast magnetic resonance imaging. Solid circle represents each study in the meta-analysis, and the circle size indicates the study size. SROC: Summary receiver operating characteristic.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Sensitivity and specificity of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 Likelihood ratio + and likelihood ratio - of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 8
Open in New Tab Full Size Figure Download Figure
Figure 8 Diagnostic odds ratio of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 9
Open in New Tab Full Size Figure Download Figure
Figure 9 Summary receiver operating characteristic curve for dynamic susceptibility contrast magnetic resonance imaging. SROC: Summary receiver operating characteristic.
Figure 10
Open in New Tab Full Size Figure Download Figure
Figure 10 Sensitivity and specificity of dynamic contrast-enhanced magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in gliomas.
Figure 11
Open in New Tab Full Size Figure Download Figure
Figure 11 Likelihood ratio + and likelihood ratio - of dynamic contrast-enhanced magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 12
Open in New Tab Full Size Figure Download Figure
Figure 12 Diagnostic odds ratio of dynamic contrast-enhanced magnetic resonance imaging in the evaluation of response to antiangiogenic therapy in recurrent gliomas.
Figure 13
Open in New Tab Full Size Figure Download Figure
Figure 13 Summary receiver operating characteristic curve for dynamic contrast-enhanced magnetic resonance imaging. SROC: Summary receiver operating characteristic.